Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biohit OyjLTS:0DRP 78 3-Year ROIIC % is 24.08 as of Dec. 2025, which is 31% below its 10-year median of 35.11. GuruFocus rates LTS:0DRP with a GF Score™ of 78/100 and a GF Value™ of €2.71 (Fairly Valued). The stock has 4 warning signs investors should review. Among 796 Medical Devices & Instruments companies, Biohit Oyj ranks better than 72.86% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Biohit Oyj's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 24.08%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Biohit Oyj's 3-Year ROIIC % or its related term are showing as below:
LTS:0DRP's 3-Year ROIIC % is ranked better than 72.86% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 1.62
vs LTS:0DRP: 24.08
Biohit Oyj (LTS:0DRP) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Biohit Oyj 3-Year ROIIC % Related Terms
Biohit Oyj 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Biohit Oyj's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0DRP vs ABT, SYK, MDT: 3-Year ROIIC % Comparison
For the Medical Devices subindustry, Biohit Oyj's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biohit Oyj 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biohit Oyj's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Biohit Oyj's 3-Year ROIIC % falls into.
Biohit Oyj's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 3.0277104 (Dec. 2025) - 0.7817196 (Dec. 2022) )
/
( 13.049 (Dec. 2025) - 3.723 (Dec. 2022) )
=
2.2459908
/
9.326
=
24.08%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Biohit Oyj (LTS:0DRP) has a 3-Year ROIIC % of 24.08 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Biohit Oyj and its competitors. This is 31% below median its historical median of 35.11. According to the industry distribution chart, Biohit Oyj ranks #216 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 27.1%.
Is Biohit Oyj's 3-Year ROIIC % too high?
Biohit Oyj's current 3-Year ROIIC % of 24.08 is 31% below median its 10-year median of 35.11. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.62. Biohit Oyj's value of 24.08 is 1386.4% above this industry median. Based on the distribution chart, Biohit Oyj ranks #216 out of 796 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Biohit Oyj has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biohit Oyj's 3-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Biohit Oyj ranks #216 out of 796 companies for 3-Year ROIIC %. This puts Biohit Oyj in the upper half of its industry. The industry median 3-Year ROIIC % is 1.62. Biohit Oyj's value of 24.08 is 1386.4% above this benchmark. While the company's 10-year median is 35.11 vs. the industry median of 1.62, Biohit Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.62, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biohit Oyj's current 3-Year ROIIC % of 24.08 is 1386.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Biohit Oyj and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biohit Oyj's current 3-Year ROIIC % is 24.08, which is 31% below median its own 10-year median of 35.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biohit Oyj stock overvalued right now?
Based on GuruFocus' analysis, Biohit Oyj (LTS:0DRP) is currently considered Fairly Valued. The stock's GF Value™ is €2.71, compared to a current price of €2.74 — trading 1.1% above its estimated fair value. The current 3-Year ROIIC % is 24.08, which is 31% below median its 10-year median of 35.11 and 1386.4% above the Medical Devices & Instruments industry median of 1.62. Biohit Oyj's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Biohit Oyj (LTS:0DRP), the current 3-Year ROIIC % is 24.08 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biohit Oyj (LTS:0DRP) Overvalued in 2026?
Based on GuruFocus' analysis, Biohit Oyj stock appears to be overvalued.
The current stock price of €2.74 is trading 1.1% above its estimated GF Value™ of €2.71.
GuruFocus considers Biohit Oyj to be Fairly Valued.
Key valuation signals for LTS:0DRP:
3-Year ROIIC %: 24.08 (31% below median its 10-year median of 35.11)
GF Value™: €2.71 vs. price of €2.74 (1.1% above fair value)
Industry Position: 1386.4% above the Medical Devices & Instruments median (#216 of 796)
No single metric tells the full story. See the LTS:0DRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products. Its products include GastroPanel quick test assesses the structure and function of the stomach lining; ColonView quick test is an immunochemical fecal occult blood test (FIT) developed; Acetium capsules protect the stomach lining from carcinogenic acetaldehyde, especially in people with acid-free stomachs. The company's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound and monoclonal antibodies.
78GF Score
Get the complete analysis for LTS:0DRP
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRP has been successfully added to your 
